We inform you that Angelini Holding S.p.A. uses cookies (small files saved on your hard disk) to improve your browsing experience on this site. Angelini Holding S.p.A. uses third party cookies that allow third parties to access personal data collected during navigation. By continuing to browse the site, by accessing any area of it or selecting an element of it (for example, an image or a link) you consent to the use of cookies. At the following link you will find our extended information on cookies with a description of the categories present and links to the information of third parties as independent data controllers and you will have the opportunity to decide which cookies to authorize or whether to deny consent to all or only some cookies CONTINUE

Board of directors

Lorenzo Tallarigo

Board Member

Born in Conflenti (CZ) in 1951, Lorenzo Tallarigo attained a Medical degree from the University of Pisa and a PMD from Harvard Business School.

He went on to gain experience in Eli Lilly, where he held various roles of increasing responsibility: clinical research, marketing, general management, eventually becoming President of International Operations.

He was the Chairman of Intercept Pharmaceuticals, which he led to the company’s IPO.
He was also Chief Executive Officer of Genextra, where he remains a board member.
He was appointed non-executive Chairman of Oxford Biomedica in 2016.
He has been on the Board of Directors of Angelini Holding S.p.A. since 1 January 2019.